The United Kingdom's publicly financed National Health Service has granted near-veto power over drug reimbursement decisions to the National Institute for Health and Clinical Excellence, an independent organization known as NICE. As a result, British health authorities are expected to adopt or deny new medical technology based on NICE's assessment of the benefits of this technology versus its impact on health-care costs. This process and the resulting delay in coverage have generated intense controversy in the UK. At the same time, NICE's operation has aroused interest in constructing a similar mechanism in the United States. At this conference, Andrea Sutcliffe, deputy chief executive of NICE, a group of British and American analysts, and an American biomedical industry representative will examine NICE’s method and its implications for U.S. policy.
What's new on AEI
|The Fed can't save the stock market again|
|Obama's IRS and AP scandals cast big chill on free speech|
|Organic industry's credibility eroded by misinformation about GE foods|
|It's not universal coverage|
Join us for a discussion of the history and future of federal and state alcohol regulation and competition, followed by a reception with beer, wine, and spirits.
Join education scholars and practitioners for a discussion about the latest NCLB research and its implications for future education policy.
What shared commitments do we have as citizens and neighbors to care for one another? How can a proper ordering of America’s political economy enable the most people to have the best life? At this event, Rep. Frank Wolf (R-VA), a longtime champion of human rights causes, and AEI President Arthur Brooks will join Wallis in addressing these and other questions.